Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinoma

Sorafenib was the first systemic therapy approved by the Food and Drug Administration to treat advanced hepatocellular carcinoma (HCC). However, sorafenib therapy is frequently accompanied by drug resistance. We aimed to explore the mechanisms of sorafenib resistance and provide feasible solutions t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell biology international 2021-09, Vol.45 (9), p.1906-1916
Hauptverfasser:	Liu, Qing‐Quan, Liu, Yu‐Wen, Xie, Yuan‐Kang, Zhang, Jian‐Hong, Song, Cai‐Xin, Wang, Jian‐Zhong, Xie, Bin‐Hui
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged antiapoptosis Antineoplastic Agents - pharmacology Carcinoma, Hepatocellular - drug therapy Cell Line, Tumor Cytotoxicity DDR2 Discoidin Domain Receptor 2 - physiology DNA nucleotidylexotransferase Drug resistance Female Flow cytometry Gene Expression Regulation, Neoplastic - drug effects HCC Hepatocellular carcinoma Humans Immunofluorescence Liver cancer Liver Neoplasms - drug therapy Male Middle Aged NF‐κB signaling Signal transduction Sorafenib - pharmacology sorafenib resistance Targeted cancer therapy Therapeutic targets Western blotting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!